 | | Vol. 14.04 – 3 February, 2022 |
| |
|
|
| ARIH1 silencing in breast cancer cells significantly attenuated cancer cell stemness in vitro and tumor formation in vivo.
[Oncogene] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators unraveled a novel LIN28/MSI2-YAP1 regulatory axis to induce the cancer stem cell-like properties, tumor growth and metastasis, independently of Let-7, which may serve as a potential therapeutic strategy for the treatment of a subset of TNBC with LIN28 overexpression.
[Oncogene] |
|
|
|
| The authors characterized the effects of iron(II)-based complexes on the structural and morphological properties of epithelial non-tumorigenic and tumorigenic breast cell lines using atomic force microscopy, flow cytometry and immunofluorescence microscopy.
[Nanoscale] |
|
|
|
| Overexpression of RBM5-AS1 facilitated proliferation, migration, invasion, epithelial-mesenchymal transition, and stemness maintenance of breast cancer cells in vitro and in vivo.
[Cell Death & Disease] |
|
|
|
| Scientists depicted the mechanism of breast cancer stem cells’ (bCSCs) response to replication stress (RS) and its clinical implication, and demonstrated that bCSCs presented a limited level of RS compared with non-bCSCs in patient samples.
[Cell Death & Disease] |
|
|
|
| Ubiquitin-specific peptidase 5 (USP5) stabilized hypoxia-inducible factor 2α (HIF2α) through its deubiquitinase activity and provided a potential therapeutic target for breast cancer.
[Journal of Cellular Physiology] |
|
|
|
| Investigators demonstrated that DNMT1 induced methylation of MEG3 promoter and played a key role in breast cancer growth through the miR-494-3p/OTUD4 axis.
[Cancer Cell International] |
|
|
|
| A transwell migration assay was used to investigate recruitment of MDA-MB-231, MCF-7, and MDA-MB-453 breast cancer cells to the osseous polycaprolactone-nano-hydroxyapatite scaffolds.
[Journal of Biomedical Materials Research Part B-Applied Biomaterials] |
|
|
|
| Researchers explored the effects of ultrasound targeted microbubble destruction-mediated transfection of SOCS3 on the biological characteristics and EMT of breast cancer stem cells.
[Bioengineered] |
|
|
|
|
| The authors describe ongoing clinical trials on druggable targets in TNBC-brain metastasis (BM) for a more targeted treatment and introduce the obstacles hindering drug delivery to the brain, bringing strategies and advancing knowledge for future steps in the treatment of patients with TNBC-BM.
[Drug Discovery Today] |
|
|
|
| Kinase fusions are currently being evaluated in breast cancer clinical trials and ongoing mechanistic investigation is exposing therapeutic vulnerabilities in patients with fusion positive disease.
[Genes Chromosomes & Cancer] |
|
|
|
|
| Veru, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and company which will evaluate the efficacy and safety of enobosarm in combination with Lilly’s abemaciclib as a second line therapy in the treatment of AR+ER+HER2- metastatic breast cancer
[Veru, Inc.] |
|
|
|
|
| 6 – 9 March, 2022
EMBL Heidelberg and Virtual |
|
|
|
|
|
| | Severo Ochoa Centre for Molecular Biology – Madrid, Spain |
|
|
|
| | University of Bristol – Bristol, United Kingdom |
|
|
|
| | The Wistar Institute – Philadelphia, Pennsylvania, United States |
|
|
|
| | Brigham and Women’s Hospital – Boston, Massachusetts, United States |
|
|
|
| | The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
